Article Text

Download PDFPDF
Preventing disease relapses in autoimmune pancreatitis with maintenance steroids: are we there yet?
  1. Phil A Hart1,
  2. Suresh T Chari2
  1. 1Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
  2. 2Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
  1. Correspondence to Dr Phil A Hart, Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, 410 West Tenth Avenue, Columbus, OH 43210, USA; philip.hart{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Autoimmune pancreatitis (AIP) is a fibro-inflammatory disease, which has defining histopathology and is characterised by a dramatic response to steroid treatment.1 Type 1 AIP describes the pancreatic manifestation of a multiorgan syndrome, currently referred to as IgG4-related disease and is frequently associated with an elevated serum IgG4 antibody level.2 This is a chronic disease with relapses occurring in 30–50% of patients within 3 years of disease onset.3 ,4 Published data suggest that low-dose maintenance steroids may decrease the risk for future disease relapse; however, this has not been demonstrated in a prospective clinical trial.5 In the present study, Masamune et al6 present their findings from a randomised controlled trial (RCT) examining the efficacy of low-dose steroids for maintenance of disease remission. We discuss this article in the context of the existing literature and identify future opportunities to improve the management of type 1 AIP.

In the present study, the authors present their findings from a multicenter, double-blind RCT using low-dose steroids for maintenance of disease remission. A total of 49 subjects were enrolled with a diagnosis of AIP based on the Japanese Pancreas Society diagnostic criteria, with all but two also meeting the International Consensus Diagnostic Criteria for AIP. Treatment naive subjects were randomised at the time of diagnosis to one of two strategies for maintenance therapy. Both groups received similar treatment over the initial 26 weeks, which consisted of high-dose steroids (prednisolone 0.6 mg/kg/day) with a taper over 12 weeks, then intermediate-term exposure to a low steroid dose (prednisolone 5–7.5 mg/day) over the next 14 weeks. At the end of 26 weeks, subjects randomised to the maintenance therapy arm continued their low steroid dose for the remainder of the 3 year study period, whereas those in the steroid cessation arm discontinued steroid use.

The …

View Full Text


  • Contributors PAH: study concept and design, literature search/acquisition of data, drafting of initial manuscript, critical revision of the manuscript, final approval of the version to be published, and study guarantor. STC: acquisition of data, critical revision of the manuscript, and final approval of the version to be published.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Pancreas
    Atsushi Masamune Isao Nishimori Kazuhiro Kikuta Ichiro Tsuji Nobumasa Mizuno Tatsuo Iiyama Atsushi Kanno Yuichi Tachibana Tetsuhide Ito Terumi Kamisawa Kazushige Uchida Hideaki Hamano Hiroaki Yasuda Junichi Sakagami Akira Mitoro Masashi Taguchi Yasuyuki Kihara Hiroyuki Sugimoto Yoshiki Hirooka Satoshi Yamamoto Kazuo Inui Osamu Inatomi Akira Andoh Kazuyuki Nakahara Hiroyuki Miyakawa Shin Hamada Shigeyuki Kawa Kazuichi Okazaki Tooru Shimosegawa